Biolinerx Ltd ADR (BLRX) Stock Price, Quote & News

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 642 9100

Fax: 972 8 642 9101

Website: www.biolinerx.com

Address:

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel

Love_To_Learn Nov. 10 at 9:31 PM

$BLRX $OST REQUIRE U BOTH ! OST AGAIN CODING

0 · Reply

BlakeTaylor12 Nov. 7 at 2:31 AM

$BLRX this might be the final nail in the coffin https://www.yahoo.com/news/articles/pill-raising-hope-one-deadliest-135331927.html

2 · Reply

TwongStocks Nov. 3 at 2:51 PM

$BLRX This abstract will also be presented at ASH. It was a real world comparison of Aphexda + G-CSF vs Plerixafor + G-CSF as a stem cell mobilzier in MM patients. https://meetings-api.hematology.org/api/abstract/vmpreview/302100 "Our prior single-institution real-world comparative analysis did not demonstrate a significant overall benefit of motixafortide compared to plerixafor for unselected MM patients undergoing stem cell mobilization and collection. However, this interim analysis of our ongoing prospective study of “poor mobilizers” suggests that motixafortide may be more efficacious than plerixafor in this subgroup of patients " They did not see any significant real-world difference between APHEXDA & plerixafor, except in poor mobilizers (defined as pbCD34+ ≤ 2/μL after 4 days of G-CSF). Which likely explains why APHEXDA has struggled to gain market share vs generic plerixafor. APHEXDA's advantage in this study was primarily with poor mobilizers.

2 · Reply

TwongStocks Nov. 3 at 2:42 PM

$BLRX NOTE: The rights to this indication now belong to Ayrmid. If Ayrmid is able to eventually get this approved as a stem cell mobilizer for sickle cell patients, then BLRX would receive royalties.

0 · Reply

TwongStocks Nov. 3 at 2:41 PM

$BLRX Abstract for the APHEXDA + natalizumab trial as a stem cell mobilizer in sinkle cell is out. Will be presented at ASH in December. https://meetings-api.hematology.org/api/abstract/vmpreview/288752 • 10 subjects enrolled • SAFETY: Grade 1-2 injection site and systemic reactions. No Grade 4 AEs, DLTs, or complicated vaso-occlusive crises. • APHEXDA monotherapy (M): Mobilized a median of 189 CD34+ cells/μ at 10-14h, with median 4.22x10^6 CD34+ cells/kg collected in a 1 BV LP. • APHEXDA + natalizumab (N+M): Mobilized a median of 312 CD34+ cells/μl at 10-14h, with median 4.89x10^6 CD34+ cells/kg collected in a 1 BV LP. "In conclusion, our first-in-human trial demonstrates the potential of M and N+M as novel G-CSF-free regimens to safely optimize HSC mobilization in SCD."

1 · Reply

Love_To_Learn Oct. 31 at 11:11 AM

$XPON $WNW $UAVS $MAXN forgot to add $BLRX apart of this

1 · Reply

tankwfwf Oct. 30 at 8:39 PM

$BLRX where's Phil's update on the new zizzwheel, He is going to have to make up some serious lies to get any interest in his new scam, because the earnings will be terrible and he will say it is because of the great new zizzwheel getting ground...... where's Phil's update on the new zizzwheel, He is going to have to make up some serious lies to get any interest in his new scam, because the earnings will be terrible and he will say it is because of the great new zizzwheel getting off the

0 · Reply

DiaJay Oct. 29 at 8:06 PM

$BLRX This should not be a publicly traded company. There is nothing of value here.

0 · Reply

gargoyl Oct. 23 at 7:53 PM

🐎 $BLRX and 🐎 $VSTM have trials with GenFleet Therapeutics for PDAC with different mechanisms of action , different target groups and are at different stages of progression along phases and trials …. Long the 🦋 👇$REGN

0 · Reply

gargoyl Oct. 21 at 7:43 PM

$BLRX 👀 can’t wait for Gloria to drop a 🐈‍⬛ catalyst… $$ $REGN $PFE Long the 🦋

0 · Reply

BioLineRx Ltd. - Special Call

Sep 29, 2025, 7:00 AM EDT - 6 weeks ago

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Aug 14, 2025, 10:44 AM EDT - 3 months ago

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:00 AM EDT - 3 months ago

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:00 AM EDT - 3 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

May 30, 2025, 1:58 PM EDT - 6 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

May 30, 2025, 7:00 AM EDT - 6 months ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 27, 2025, 12:55 PM EDT - 6 months ago

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

May 27, 2025, 7:00 AM EDT - 6 months ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 20, 2025, 7:00 AM EDT - 6 months ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Mar 31, 2025, 10:52 AM EDT - 8 months ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:00 AM EDT - 8 months ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:00 AM EDT - 8 months ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

Jan 21, 2025, 7:00 AM EST - 10 months ago

BioLineRx Issues Letter to Shareholders

Jan 17, 2025, 7:00 AM EST - 10 months ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 6, 2025, 2:01 PM EST - 11 months ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Jan 6, 2025, 8:57 AM EST - 11 months ago

BioLineRx Announces $10 Million Registered Direct Offering

Nov 25, 2024, 10:58 AM EST - 1 year ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Nov 25, 2024, 7:00 AM EST - 1 year ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 21, 2024, 6:30 AM EST - 1 year ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 20, 2024, 7:19 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Oct 16, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Sep 17, 2024, 1:01 PM EDT - 1 year ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Aug 15, 2024, 3:03 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

May 30, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 28, 2024, 5:56 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

May 28, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 24, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 22, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 17, 2024, 5:00 PM EDT - 1 year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 6, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

Apr 17, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 1, 2024, 9:00 AM EDT - 1 year ago

BioLineRx Announces $6 Million Registered Direct Offering

Mar 26, 2024, 11:38 AM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

Mar 4, 2024, 7:00 AM EST - 1 year ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Feb 28, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 16, 2024, 7:00 AM EST - 1 year ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Dec 21, 2023, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 4, 2023, 6:42 PM EST - 2 years ago

BioLineRx: Still A Buy, With Some Questions

Dec 2, 2023, 11:25 PM EST - 2 years ago

BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges

Nov 20, 2023, 1:54 PM EST - 2 years ago

BioLineRx Ltd. (BLRX) Q3 2023 Earnings Call Transcript

Nov 20, 2023, 7:00 AM EST - 2 years ago

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Nov 13, 2023, 7:00 AM EST - 2 years ago

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

Love_To_Learn Nov. 10 at 9:31 PM

$BLRX $OST REQUIRE U BOTH ! OST AGAIN CODING

0 · Reply

BlakeTaylor12 Nov. 7 at 2:31 AM

$BLRX this might be the final nail in the coffin https://www.yahoo.com/news/articles/pill-raising-hope-one-deadliest-135331927.html

2 · Reply

TwongStocks Nov. 3 at 2:51 PM

2 · Reply

TwongStocks Nov. 3 at 2:42 PM

$BLRX NOTE: The rights to this indication now belong to Ayrmid. If Ayrmid is able to eventually get this approved as a stem cell mobilizer for sickle cell patients, then BLRX would receive royalties.

0 · Reply

TwongStocks Nov. 3 at 2:41 PM

1 · Reply

Love_To_Learn Oct. 31 at 11:11 AM

$XPON $WNW $UAVS $MAXN forgot to add $BLRX apart of this

1 · Reply

tankwfwf Oct. 30 at 8:39 PM

0 · Reply

DiaJay Oct. 29 at 8:06 PM

$BLRX This should not be a publicly traded company. There is nothing of value here.

0 · Reply

gargoyl Oct. 23 at 7:53 PM

0 · Reply

gargoyl Oct. 21 at 7:43 PM

$BLRX 👀 can’t wait for Gloria to drop a 🐈‍⬛ catalyst… $$ $REGN $PFE Long the 🦋

0 · Reply

tankwfwf Oct. 19 at 8:48 PM

$BLRX save your self some headaches and get out of this scam, Phil is worse than a shit eating fly.......check out LAES AND MAKE SOME MONEY.........

0 · Reply

gargoyl Oct. 16 at 5:35 PM

$BLRX 👀 not if , it’s when the next catalyst pops .. Phil 🥷🏿 has built a foundation over the years that will see exponential growth. 🎯 Target $12 before end year . $REGN $PFE $XBI 👇

0 · Reply

Eran1983 Oct. 16 at 8:32 AM

$BLRX the CEO of this company took money from many shareholders. Until he will bring this company to 20 X share value no respect to this man

3 · Reply

gargoyl Oct. 15 at 3:30 PM

$BLRX 👀 pg. 16 BiolineRx Corp. Presentation speaks volumes, the link below shares pipeline as well as BLRX stake of 40% increases in JV w/ Hemispherian as it contributes $$ to devmnt, sheer genius Phil 🥷🏿 up to 70% Then there's Gloria & Ayrmid/Gamida Partnerships w/ APHEXDA revenue and catalysts, not to mention Columbia Univ., Washington Univ. and St Jude Children’s Research Hospital collaborations on PDAC and Sickle Cell diseases and cancer. Long the 🦋 $REGN $$PFE Currently 16M Corp valuation is off by 10x 🎯, watch this !!!! Mark this post . https://ir.biolinerx.com/static-files/f1fbb06b-cb0e-4902-b166-f780a049ba38

0 · Reply

gargoyl Oct. 13 at 7:25 PM

$BLRX spread wide off charts 📈 She’s about to run 👀 🏃‍♀️ $XBI $IBB

0 · Reply

Halbalidiya Oct. 13 at 1:20 PM

$BLRX gargoyl is phil

1 · Reply

BEATOFtheMARKET Oct. 9 at 6:54 PM

Results of list 9/26/25 $BLK $BLKB $BLMN $BLRX Cycle Trading Signal plugged into AI 🔥 list.

0 · Reply

gargoyl Oct. 8 at 10:10 PM

$BLRX a “ W “ formation calculation from the center spike to the low calculation implies a .75 cent move to $5.25 and possibly more if it’s not just charting and an entity is accumulating.. let’s see tomorrow.. long the 🦋 $XBI pop perfect storm

0 · Reply

gargoyl Oct. 8 at 4:38 PM

$BLRX 👀 my little brother hasn’t been around in a while. He is so special. He sees things, patterns, deep correlations, algo sh$T. He walked into my trading room , pointed to this chart 📊 and said go long , average in, he likes the SP action, the volume steadying, the chart itself over different time frames is at a pivotal point … He’s 11 years old .. a savant maybe or just wired for technical numbers and the past vs the future pattern. $XBI $IBB $REGN

0 · Reply

gargoyl Oct. 8 at 6:47 AM

$BLRX 👀 $5.50 🎯 this week 2 of 2 $XBI

0 · Reply

gargoyl Oct. 8 at 6:44 AM

$XBI 1 of 2 $BLRX 👇

0 · Reply

gargoyl Oct. 7 at 5:30 PM

$BLRX 👀 3 of 3 Longest the 🦋

0 · Reply

Market Cap	15.10M
Revenue (ttm)	28.94M
Net Income (ttm)	-9.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-31.86%
Debt to Equity Ratio	0.56

Volume	31,300
Avg Vol	37,496
Day's Range	N/A - N/A
Shares Out	4.35M
Stochastic %K	30%
Beta	1.34
Analysts	Strong Sell
Price Target	$26.00